Эффективность и безопасность апиксабана: что изменилось за 12 лет его использования в реальной клинической практике? [PDF]
, 2023 This review examines the position of apixaban among other direct oral anticoagulants in patients with atrial fibrillation (AF) and venous thrombosis in randomized clinical trials and real clinical practice.
E. Р. Panchenko +1 more
core +2 more sources
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
Рациональная фармакотерапия в кардиологии, 2015 Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed ...
V. A. Sulimov +2 more
doaj +1 more source
СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ ДАБИГАТРАНА ИДАРУЦИЗУМАБ: ЧТО ИЗВЕСТНО НА СЕГОДНЯШНИЙ ДЕНЬ [PDF]
, 2018 Idaruzizumab (Praxbind©) is a specific reversal agent for dabigatran, which is a humanized Fab fragment of a monoclonal antibody. Immediately after administration, the drug binds to dabigatran and its metabolites, inhibiting 99% of the anti-coagulant ...
Olga Shakhmatova O. +1 more
core +4 more sources
The problem of choosing an anticoagulant for stroke prevention in patients with atrial fibrillation
Медицинский совет, 2014 The article is a literature review on the problem of thromboembolic complications in non-valvular atrial fibrillation, the peculiarities of anticoagulant therapy and challenges associated with the selection of drugs for stroke prevention.
EL Dolgova, IM Sokolov, YG Schwarz
doaj +1 more source
Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran [PDF]
, 2020 This review focuses on some aspects of anticoagulant therapy in the updated clinical guidelines for atrial fibrillation of the European society of cardiology, published in 2020.
E. P. Panchenko, E. S. Kropacheva
core +2 more sources
The place of dabigatran in the treatment of patients with atrial fibrillation in the light of modern recommendations [PDF]
, 2023 This review is devoted to the aspects of anticoagulant therapy in patients with atrial fibrillation in the light of the modern understanding of this type of arrhythmia as a polymorbid continuously developing syndrome. According to experts, the management
E. P. Panchenko, E. S. Kropacheva
core +2 more sources
Выбор антикоагулянта у пациентов с фибрилляцией предсердий, возникшей в условиях СOVID-19 (разбор клинического случая) [PDF]
, 2022 The COVID-19 epidemic is accompanied by an increase in the frequency of rhythm disturbances and, in particular, atrial fibrillation. This article is a clinical analysis of a patient whose atrial fibrillation (fluttering) occurred due to an infection ...
E. P. Panchenko +1 more
core +2 more sources
Атеротромбоз, 2016 В статье обсуждаются современные представления о подходах к антитромботической терапии после острого коронарного синдрома (ее длительность, сочетание препаратов, особенности в различных клинических ситуациях).
doaj +1 more source
Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease [PDF]
, 2021 Atrial fibrillation (AF) is the most common cardiac arrhythmia, which is associated with an increased risk of cardiovascular death. The latter is partly due to the common combination with coronary artery disease (CAD). If indicated, patients with AF need
A. A. Shavarov, Zh. D. Kobalava
core +2 more sources
СНИЖЕНИЕ РИСКА СЕРДЕЧНО-СОСУДИСТОЙ СМЕРТНОСТИ И ИНСУЛЬТА У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
Атеротромбоз, 2016 Фибрилляция предсердий (ФП) является наиболее частым кардиальным источником системной эмболии и кардиоэмболического инсульта. «Новые» пероральные антикоагулянты рекомендованы для предотвращения инсульта у больных с неклапанной ФП и снижения сердечно ...
doaj +1 more source